{"gene":"CYP11B2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1991,"finding":"CYP11B2 protein (P450aldo) catalyzes all three steps required for aldosterone biosynthesis from deoxycorticosterone: 11β-hydroxylation, 18-hydroxylation, and 18-oxidation. Expression of CYP11B2 cDNA in COS-1 cells demonstrated that only CYP11B2 (not CYP11B1) could synthesize aldosterone from deoxycorticosterone, and CYP11B2 could also 18-hydroxylate cortisol/corticosterone.","method":"Heterologous cDNA expression in COS-1 cells with steroid product analysis","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic reconstitution in cell expression system; replicated in multiple independent studies (PMID:2256920, 1594605)","pmids":["1775135"],"is_preprint":false},{"year":1990,"finding":"CYP11B2 (P-450aldo) expressed in COS-7 cells preferentially catalyzes the complete conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone, whereas CYP11B1 (P-450(11)β) substantially fails to produce aldosterone from the same substrate.","method":"Heterologous cDNA expression in COS-7 cells with steroid product analysis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic reconstitution in cell expression system; consistent with multiple independent replications","pmids":["2256920"],"is_preprint":false},{"year":1992,"finding":"Mutations R181W and V386A in CYP11B2 cause CMO-II deficiency: R181W reduces 18-hydroxylase and abolishes 18-oxidase activities while leaving 11β-hydroxylase activity intact; V386A causes a small reduction in 18-hydroxycorticosterone production. Both mutations together compound to eliminate aldosterone synthesis.","method":"Site-directed mutagenesis of CYP11B2 cDNA with expression in cultured cells and steroid product analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — active-site mutagenesis with in vitro activity assay, confirmed in multiple affected kindreds","pmids":["1594605"],"is_preprint":false},{"year":1993,"finding":"A 5-nucleotide deletion in exon 1 of CYP11B2 causes a frameshift and premature stop codon, resulting in complete absence of P-450C18 protein and total lack of aldosterone biosynthesis (CMO-I deficiency), demonstrating CYP11B2 is the sole enzyme for corticosterone methyl oxidase I activity.","method":"Molecular genetic analysis (PCR, sequencing, RFLP) of patient CYP11B2 gene","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function mutation with defined biochemical phenotype; no in vitro reconstitution of null allele but frameshift abolishing protein is definitive","pmids":["8439335"],"is_preprint":false},{"year":1995,"finding":"The T318M mutation in CYP11B2 causes CMO-II deficiency. When expressed singly and in parental allele pairs in cDNA expression vectors, neither the T318M/V386A allele nor the R181W/ΔC372 allele showed measurable enzymatic activity, yet the clinical phenotype is CMO-II rather than CMO-I, suggesting other factors modulate phenotypic expression.","method":"Site-directed mutagenesis and cDNA expression with in vitro steroid activity assay","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mutagenesis; single lab, limited replication","pmids":["7485152"],"is_preprint":false},{"year":2002,"finding":"Human CYP11B2 expressed in fission yeast (Schizosaccharomyces pombe) localizes to mitochondria via its endogenous signal sequence, and converts 11-deoxycorticosterone to corticosterone, 18-hydroxycorticosterone, and aldosterone in vivo. A fission yeast ferredoxin-domain protein (etp1) was identified that can functionally replace adrenodoxin as an electron donor to CYP11B2 in a reconstituted steroid hydroxylation assay.","method":"Heterologous expression in S. pombe, Western blot/fluorescence/electron microscopy for localization, in vitro reconstituted steroid hydroxylation assay with bacterially expressed etp1","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution of electron transfer to CYP11B2 with orthologous protein, confirmed by multiple localization methods and in vivo substrate conversion","pmids":["11841224"],"is_preprint":false},{"year":1997,"finding":"Angiotensin II and potassium regulate CYP11B2 transcription through two cis-elements in the 5'-flanking region: a CRE-like element at -71/-64 (binding CREB proteins) and an SF-1/COUP-TF binding element at -129/-114 (Ad5). Both calcium and cAMP signaling pathways converge on these same elements to drive CYP11B2 expression.","method":"Transient transfection with luciferase reporter constructs, deletion/mutation analysis, DNase I footprinting, electrophoretic mobility shift assay (EMSA) in H295R cells","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (reporter assay, EMSA, footprinting, mutation analysis) in relevant cell line","pmids":["9139807"],"is_preprint":false},{"year":1996,"finding":"Calcium signaling pathways (activated by Ang II, K+, BAYK8644, ionomycin) regulate human CYP11B2 transcription in H295R adrenocortical cells. Protein kinase C activation did not alter CYP11B2 reporter gene expression.","method":"Transient transfection of luciferase reporter construct with CYP11B2 5'-flanking DNA in H295R and Y-1 adrenocortical cell lines","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter gene assay with pharmacological pathway dissection; single lab, multiple conditions tested","pmids":["8969900"],"is_preprint":false},{"year":2004,"finding":"COUP-TFI binds the Ad5 element (-129/-114) of the CYP11B2 promoter and activates transcription. Ubc9 (SUMO E2 conjugase) and PIAS1 (SUMO E3 ligase) interact with COUP-TFI and act as transcriptional coactivators of CYP11B2; sumoylation activity is separable from coactivator function. All three proteins are recruited to the endogenous CYP11B2 promoter in ChIP assays.","method":"EMSA, transient transfection, yeast two-hybrid, coimmunoprecipitation, chromatin immunoprecipitation (ChIP), siRNA knockdown in H295R cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including ChIP, Co-IP, EMSA, reporter assay, and siRNA loss-of-function","pmids":["15611122"],"is_preprint":false},{"year":2008,"finding":"SF-1 (steroidogenic factor-1) overexpression dramatically inhibits CYP11B2 mRNA expression and aldosterone production in adrenocortical H295R cells, while SF-1 knockdown by siRNA reverses this inhibition. Conversely, SF-1 overexpression increases CYP11B1 expression, demonstrating opposing regulatory roles. A minimal level of SF-1 is required for basal expression of both genes.","method":"Doxycycline-inducible SF-1 overexpression, siRNA knockdown, real-time RT-PCR, immunoassay in H295R/TR/SF-1 cells","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain- and loss-of-function with quantitative mRNA and hormone readouts; multiple orthogonal approaches","pmids":["18974272"],"is_preprint":false},{"year":2011,"finding":"PPARγ suppresses CYP11B2 expression and aldosterone secretion via the Ad1/CRE element in the CYP11B2 5'-flanking region. PPARγ activation by pioglitazone inhibits CaMKI-mediated CYP11B2 transcriptional activation. The PPARγ L466A/E469A mutant abolishes this suppression, indicating ligand-binding domain requirement.","method":"Transient transfection with promoter-reporter constructs, PPARγ overexpression/mutation, CaMKI transfection, pharmacological inhibition in H295R cells","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with mutagenesis and overexpression; single lab, multiple pathway conditions","pmids":["21106862"],"is_preprint":false},{"year":2015,"finding":"Klotho (KL) regulates CYP11B2 expression in adrenal zona glomerulosa cells: KL silencing upregulates and KL overexpression downregulates CYP11B2 in human adrenocortical cells. KL deficiency decreases SF-1 expression (a negative regulator of CYP11B2) and increases ATF2 phosphorylation (a positive regulator), providing a mechanistic link. KL and CYP11B2 proteins co-localize in adrenal zona glomerulosa cells.","method":"siRNA knockdown, overexpression, Western blot, immunofluorescence co-localization, immunoassay in human adrenocortical cells and KL+/- mice","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with mechanistic follow-up; single lab, in vitro and in vivo","pmids":["26471128"],"is_preprint":false},{"year":2000,"finding":"The CRE/Ad1 cis-element in the CYP11B2 promoter is required for basal expression but is not sufficient for hormonal regulation by angiotensin II; mutation of this element abolishes basal expression while retaining agonist response, suggesting additional cis-elements mediate Ang II induction. Both ATF-2 and CREB bind this element, but only ATF-2 complexes match those in H295R nuclear extract.","method":"Transient transfection with reporter constructs, promoter deletion/mutation, EMSA with recombinant transcription factors and H295R nuclear extracts","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with mutagenesis and EMSA; single lab, multiple methods","pmids":["11196473"],"is_preprint":false},{"year":2009,"finding":"CYP11B2 requires the adrenodoxin/adrenodoxin reductase electron transfer system for catalytic activity. A stable cell line co-expressing CYP11B2 with adrenodoxin and adrenodoxin reductase was established, demonstrating that FAD286 inhibits CYP11B2 competitively with a Ki of 0.8 nM using 11-deoxycorticosterone as substrate.","method":"Stable cell transfection, in vitro enzyme activity assay with radiolabeled substrate, competitive kinetics analysis","journal":"Analytical biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted assay with kinetic characterization; single lab","pmids":["19622340"],"is_preprint":false},{"year":1995,"finding":"CYP11B2 (P450aldo) is localized specifically to zona glomerulosa cells of the rat adrenal cortex, while CYP11B1 (P45011β) is in zona fasciculata. A novel cell layer lacking both enzymes exists between zones and contains adrenal stem cells. Angiotensin II stimulation (via Na-deficiency) increases P450aldo-containing zona glomerulosa cell number and triggers proliferation of cells in this intermediate zone, which then migrate outward.","method":"Immunohistochemistry, double immunostaining, BrdU pulse-chase in rat adrenal sections","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization with functional consequence (proliferation response to Ang II); single lab","pmids":["7588405"],"is_preprint":false},{"year":1997,"finding":"CYP11B2 (P450aldo) mRNA and protein expression in rat adrenal zona glomerulosa is upregulated approximately 8.5-fold by dietary sodium restriction (which elevates angiotensin II) and this upregulation is blocked by the selective AT1 receptor antagonist E4177 but not by the AT2 antagonist PD123177, demonstrating that CYP11B2 expression is regulated specifically through the AT1 receptor.","method":"RT-PCR with specific primers, immunoblot analysis, pharmacological receptor antagonism in rat adrenal gland","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological dissection with quantitative mRNA and protein readouts; single lab","pmids":["9430819"],"is_preprint":false},{"year":2014,"finding":"GnRH acting through ectopically expressed GnRH receptor (GnRHR) increases CYP11B2 reporter activity and aldosterone production in H295R cells in a concentration-dependent manner. These effects are blocked by calcium signaling inhibitors KN93 and calmidazolium, placing GnRHR-mediated CYP11B2 regulation upstream of the calcium/calmodulin kinase pathway.","method":"Transient transfection with CYP11B2 reporter, doxycycline-inducible GnRHR cell line, pharmacological inhibition, RT-PCR, immunoassay","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with pharmacological pathway placement; single lab, multiple conditions","pmids":["24472523"],"is_preprint":false},{"year":2016,"finding":"Atractylenolide-I (AT-I) selectively covalently binds CYP11B2 at Cys450 (via C8/C9 epoxide intermediate) in the catalytic pocket, disrupts heme-CYP11B2 interaction, and inactivates aldosterone synthesis. The selectivity over CYP11B1 is due to Ala320 in CYP11B2 (versus a different residue in CYP11B1). This covalent inhibition suppresses aldosterone but not cortisol production.","method":"Chemical biology covalent binding studies, molecular docking, cell-based steroid synthesis assay, in vivo hyperaldosteronism model","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mechanistic covalent binding characterization with structural rationale and functional readout; single lab","pmids":["35127376"],"is_preprint":false},{"year":1995,"finding":"Stable expression of CYP11B2 cDNA in MA-10 Leydig tumor cells demonstrates the enzyme converts DOC to corticosterone, 18-OH-corticosterone, aldosterone, and small amounts of 18-OH-DOC. Corticosterone is more efficiently converted to 18-OH-corticosterone than is DOC. CYP11B2 (but not CYP11B1) can also transform 18-OH-DOC to 18-OH-corticosterone but cannot convert 18-OH-DOC to aldosterone.","method":"Stable transfection of MA-10 cells with CYP11B2 cDNA, enzyme activity assay with radiolabeled substrates, Northern blot","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — stable reconstitution system with substrate panel; single lab","pmids":["7779756"],"is_preprint":false},{"year":2016,"finding":"CYP11B2 metabolizes spironolactone (producing 11β-OH-, 18-OH-, and 19-OH-spironolactone) and canrenone (producing 11β-OH-, 18-OH-canrenone, and the CYP11B2-specific 11β,18-diOH-canrenone) via its hydroxylase activities. Binding constants for these exogenous substrates are comparable to natural substrates. 11β-OH-spironolactone retains mineralocorticoid receptor antagonist activity, while other hydroxylation products lose antagonist properties.","method":"In vitro assay with purified CYP11B2, spectroscopic binding assay, preparative-scale whole-cell biotransformation, HPLC purification, NMR structural characterization of metabolites, mineralocorticoid receptor transactivation assay","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — purified enzyme assay with structural characterization of products by NMR; multiple substrates and functional validation","pmids":["27125452"],"is_preprint":false},{"year":2008,"finding":"The S308P mutation in CYP11B2 (located within alpha-helix I near the heme-binding active site per structural modeling) causes complete loss of enzyme activity when expressed in vitro. However, dexamethasone suppressed residual aldosterone/metabolite levels in affected subjects in vivo, suggesting some mineralocorticoid biosynthesis occurs through an alternative pathway in vivo.","method":"Sequencing, in vitro functional characterization of mutant CYP11B2, structural homology modeling, in vivo dexamethasone suppression test","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of null mutant; single lab, limited replication","pmids":["19116236"],"is_preprint":false},{"year":2011,"finding":"The CYP11B2 and CYP11B1 promoters diverged due to insertion of Alu and L1 transposable elements. Alu elements act as enhancers for both genes regardless of orientation. The Ad5 and SF-1 binding elements in the proximal core promoter are required for basal expression; mutation of Ad5 reduces activity to minimal levels. ERRα is identified as the transcription factor binding the Ad5 site during basal CYP11B2 expression.","method":"Promoter deletion/mutation reporter assays, sequence analysis, transcription factor identification by reporter assay in H295R cells","journal":"Steroids","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter dissection with mutagenesis; single lab, multiple elements tested","pmids":["22079243"],"is_preprint":false},{"year":2014,"finding":"miR-193a-3p directly targets the 3'-UTR of CYP11B2 mRNA (validated by luciferase reporter with wild-type vs. mutated binding site) and downregulates CYP11B2 mRNA and protein expression. Overexpression of miR-193a-3p in H295R cells inhibits aldosterone secretion, cell proliferation, induces G1-phase arrest, and promotes apoptosis; these effects are reversed by CYP11B2 overexpression.","method":"Luciferase 3'-UTR reporter assay, qRT-PCR, Western blot, miR mimic transfection, flow cytometry, ELISA in H295R cells","journal":"International journal of experimental pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'-UTR luciferase validation with rescue experiment; single lab, multiple functional readouts","pmids":["29665181"],"is_preprint":false},{"year":2014,"finding":"miR-10b (hypoxia-inducible) negatively regulates CYP11B2 (and CYP11B1) mRNA by targeting their 3'-UTRs, as validated by luciferase reporter assays with CYP11B2 3'-UTR constructs combined with miR-10b overexpression and knockdown in H295R cells.","method":"miRNA array profiling, luciferase 3'-UTR reporter assay, miR overexpression/knockdown in H295R cells","journal":"Marine pollution bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'-UTR reporter validation with gain- and loss-of-function; single lab","pmids":["24768260"],"is_preprint":false},{"year":1995,"finding":"The CYP11B2 promoter contains a polymorphism at position -344 that influences binding of the transcriptional regulatory protein SF-1. This polymorphism and an intron 2 gene conversion (replacing CYP11B2 sequence with CYP11B1 sequence) are in linkage disequilibrium, defining haplotypes with population frequency differences between Blacks and Whites.","method":"PCR-based genotyping, linkage disequilibrium analysis, transcription factor binding inference from sequence analysis","journal":"Endocrine research","confidence":"Low","confidence_rationale":"Tier 4 / Weak — SF-1 binding at -344 inferred from sequence; no direct binding experiment reported in this abstract","pmids":["7588407"],"is_preprint":false},{"year":2016,"finding":"RO6836191 is a competitive inhibitor of CYP11B2 (aldosterone synthase) with Ki of 13 nM and >100-fold selectivity over CYP11B1 in vitro. In cynomolgus monkeys, it inhibits aldosterone synthesis without affecting ACTH-stimulated cortisol. In healthy human subjects, it completely suppresses plasma and urine aldosterone across a dose range without affecting cortisol up to 360 mg.","method":"In vitro enzyme inhibition assay (Ki determination), in vivo pharmacology in cynomolgus monkeys, Phase I clinical study in healthy volunteers","journal":"Hypertension","confidence":"High","confidence_rationale":"Tier 1 / Strong — competitive kinetics in vitro confirmed by in vivo pharmacology across species including humans; multiple orthogonal methods","pmids":["27872236"],"is_preprint":false}],"current_model":"CYP11B2 (aldosterone synthase) is a mitochondrial cytochrome P450 enzyme localized to adrenal zona glomerulosa cells that catalyzes the three-step conversion of 11-deoxycorticosterone to aldosterone (11β-hydroxylation → 18-hydroxylation → 18-oxidation), requires adrenodoxin/adrenodoxin reductase for electron transfer, and is transcriptionally regulated by angiotensin II (via AT1R-calcium/CaMK pathway) and potassium through shared CRE/Ad1 and SF-1/COUP-TF cis-elements in its promoter, with additional regulation by SF-1 (inhibitory at high levels), PPARγ, Klotho, Ubc9/PIAS1 coactivators of COUP-TFI, and post-transcriptional control by miR-193a-3p and miR-10b targeting its 3'-UTR."},"narrative":{"mechanistic_narrative":"CYP11B2 (aldosterone synthase) is the mitochondrial cytochrome P450 enzyme that catalyzes the terminal steps of aldosterone biosynthesis in adrenal zona glomerulosa cells, converting 11-deoxycorticosterone to aldosterone through sequential 11β-hydroxylation, 18-hydroxylation, and 18-oxidation reactions [PMID:1775135, PMID:2256920]. Heterologous reconstitution established that only CYP11B2 — not the closely related CYP11B1 — completes the full conversion to aldosterone, while it can also 18-hydroxylate other steroid substrates [PMID:1775135, PMID:7779756]. Catalysis depends on the adrenodoxin/adrenodoxin reductase electron-transfer system [PMID:19622340], and the enzyme localizes to mitochondria via its endogenous targeting sequence, where a ferredoxin-domain donor can functionally substitute for adrenodoxin [PMID:11841224]. Loss-of-function mutations partition the biosynthetic defect by step: a frameshift abolishing the protein causes CMO-I deficiency (loss of corticosterone methyl oxidase I activity) [PMID:8439335], whereas active-site missense mutations such as R181W, T318M, and S308P selectively impair 18-hydroxylase/18-oxidase steps to produce CMO-II deficiency [PMID:1594605, PMID:7485152, PMID:19116236]. CYP11B2 transcription is driven by angiotensin II (acting through the AT1 receptor) and potassium via a calcium/CaMK signaling pathway that converges on a proximal CRE/Ad1 element and an SF-1/COUP-TF (Ad5) element in the 5'-flanking region [PMID:9139807, PMID:8969900, PMID:9430819, PMID:11196473]. This promoter is modulated by COUP-TFI together with Ubc9/PIAS1 coactivators [PMID:15611122], by ERRα at the Ad5 site [PMID:22079243], and is suppressed by high SF-1, PPARγ, and Klotho [PMID:18974272, PMID:21106862, PMID:26471128], with post-transcriptional repression by miR-193a-3p and miR-10b targeting the 3'-UTR [PMID:29665181, PMID:24768260]. Its enzymatic specificity underlies the development of selective aldosterone synthase inhibitors as antihypertensive agents [PMID:27872236, PMID:35127376].","teleology":[{"year":1991,"claim":"Established the core catalytic identity of CYP11B2 — that a single enzyme performs all three oxidative steps of aldosterone synthesis, distinguishing it from CYP11B1 which cannot.","evidence":"Heterologous cDNA expression in COS-1/COS-7 cells with steroid product analysis comparing CYP11B2 and CYP11B1","pmids":["1775135","2256920"],"confidence":"High","gaps":["Did not resolve the structural basis for the bifunctional 18-oxidase activity","Did not address electron-donor requirements in vivo"]},{"year":1995,"claim":"Mapped the substrate panel and intermediate flux of the enzyme, showing corticosterone is converted more efficiently than DOC and that 18-OH-DOC is not a productive intermediate for aldosterone.","evidence":"Stable transfection in MA-10 Leydig cells with radiolabeled substrate panel and Northern blot","pmids":["7779756"],"confidence":"Medium","gaps":["Single lab; in vitro reconstitution may not reflect zona glomerulosa kinetics","No structural model for substrate channeling"]},{"year":1995,"claim":"Localized CYP11B2 specifically to the zona glomerulosa and linked angiotensin II to expansion of aldosterone-producing cells, connecting enzyme expression to adrenal zonation and cell proliferation.","evidence":"Immunohistochemistry, double immunostaining, and BrdU pulse-chase in rat adrenal sections","pmids":["7588405"],"confidence":"Medium","gaps":["Rat model; human zonation dynamics not directly tested","Stem cell migration mechanism not molecularly defined"]},{"year":1993,"claim":"Defined the genotype-phenotype basis for inherited aldosterone deficiency, showing protein-null mutations cause CMO-I deficiency and step-selective active-site mutations cause CMO-II deficiency.","evidence":"Patient gene analysis (frameshift) plus site-directed mutagenesis of R181W/V386A/T318M/S308P with in vitro activity assays","pmids":["8439335","1594605","7485152","19116236"],"confidence":"Medium","gaps":["CMO-II vs CMO-I phenotypic distinction not fully explained by in vitro activity","S308P case suggested an alternative in vivo mineralocorticoid pathway not yet identified"]},{"year":1997,"claim":"Identified the cis-regulatory architecture by which angiotensin II and potassium control CYP11B2 transcription, defining the CRE/Ad1 and SF-1/COUP-TF (Ad5) elements where calcium and cAMP pathways converge.","evidence":"Reporter assays, deletion/mutation analysis, DNase I footprinting, and EMSA in H295R cells; AT1-receptor-specific pharmacology in rat adrenal","pmids":["9139807","8969900","9430819","11196473"],"confidence":"High","gaps":["CRE/Ad1 alone insufficient for Ang II induction — additional inducible elements not fully mapped","Relative contribution of ATF-2 vs CREB at the element unresolved"]},{"year":2002,"claim":"Confirmed mitochondrial targeting and the electron-transfer requirement, showing a ferredoxin-domain protein can functionally replace adrenodoxin to support catalysis.","evidence":"S. pombe heterologous expression with imaging-based localization and reconstituted hydroxylation assay using bacterially expressed etp1","pmids":["11841224"],"confidence":"High","gaps":["Whether endogenous human adrenodoxin coupling is rate-limiting in vivo not addressed","No structural detail of the CYP11B2-redox partner interface"]},{"year":2008,"claim":"Expanded the transcription-factor network, identifying COUP-TFI/Ubc9/PIAS1 as activators at Ad5 and SF-1 and PPARγ/Klotho as suppressors, revealing reciprocal regulation of CYP11B2 versus CYP11B1.","evidence":"EMSA, Y2H, Co-IP, ChIP, siRNA, inducible overexpression and reporter assays in H295R cells; Klotho studies in human cells and KL+/- mice","pmids":["15611122","18974272","21106862","26471128"],"confidence":"Medium","gaps":["Integration of multiple opposing regulators into a single quantitative model not established","Most evidence from H295R cell line; in vivo relevance of each factor varies"]},{"year":2014,"claim":"Established post-transcriptional control of CYP11B2 by miRNAs targeting its 3'-UTR, linking miR-193a-3p and miR-10b to aldosterone output and adrenocortical cell behavior.","evidence":"3'-UTR luciferase reporter validation, miR mimic/knockdown, rescue experiments, and functional assays in H295R cells","pmids":["29665181","24768260"],"confidence":"Medium","gaps":["Physiological contexts driving these miRNAs in vivo not established","Single-lab reporter validations"]},{"year":2016,"claim":"Demonstrated CYP11B2 as a tractable pharmacological target by characterizing selective competitive inhibitors and a covalent inactivator that spare CYP11B1/cortisol.","evidence":"In vitro Ki determination, structural/docking rationale (Ala320, Cys450), and in vivo pharmacology in monkeys and humans; CYP11B2 also metabolizes spironolactone/canrenone","pmids":["27872236","35127376","27125452"],"confidence":"High","gaps":["Long-term in vivo selectivity and resistance not addressed","Structural basis of B2/B1 selectivity inferred rather than crystallographically resolved"]},{"year":null,"claim":"The full integration of upstream GnCa signaling, the complete cis/trans regulatory network, and a high-resolution structural model of substrate/inhibitor selectivity into a unified mechanistic picture remains open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimental atomic structure of human CYP11B2 in the timeline","Alternative in vivo mineralocorticoid pathway implied by S308P case unidentified","Quantitative hierarchy among the many activators/repressors not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,5,13,18,19]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,18,19]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,18]}],"complexes":[],"partners":["FDX1","COUP-TFI","UBC9","PIAS1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P19099","full_name":"Cytochrome P450 11B2, mitochondrial","aliases":["Aldosterone synthase","ALDOS","Aldosterone-synthesizing enzyme","CYPXIB2","Corticosterone 18-monooxygenase, CYP11B2","Cytochrome P-450Aldo","Cytochrome P-450C18","Steroid 11-beta-hydroxylase, CYP11B2","Steroid 18-hydroxylase"],"length_aa":503,"mass_kda":57.6,"function":"A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure (PubMed:11856349, PubMed:12530636, PubMed:1518866, PubMed:15356073, PubMed:1594605, PubMed:1775135, PubMed:22446688, PubMed:23322723, PubMed:9814482, PubMed:9814506). Catalyzes three sequential oxidative reactions of 11-deoxycorticosterone (21-hydroxyprogesterone), namely 11-beta hydroxylation, followed by two successive oxidations at C18 yielding 18-hydroxy and then 18-oxo intermediates (that would not leave the enzyme active site during the consecutive hydroxylation reactions), ending with the formation of aldosterone (PubMed:11856349, PubMed:12530636, PubMed:1518866, PubMed:1594605, PubMed:1775135, PubMed:22446688, PubMed:23322723, PubMed:9814506). Can also produce 18-hydroxycortisol and 18-oxocortisol, derived from successive oxidations of cortisol at C18, normally found at very low levels, but significantly increased in primary aldosteronism, the most common form of secondary hypertension (PubMed:15356073, PubMed:9814482). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) (PubMed:11856349, PubMed:1594605, PubMed:23322723, PubMed:9814506). Could also be involved in the androgen metabolic pathway (Probable)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/P19099/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP11B2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP11B2","total_profiled":1310},"omim":[{"mim_id":"617027","title":"HYPERALDOSTERONISM, FAMILIAL, TYPE IV; HALD4","url":"https://www.omim.org/entry/617027"},{"mim_id":"613815","title":"CYTOCHROME P450, FAMILY 21, SUBFAMILY A, POLYPEPTIDE 2; CYP21A2","url":"https://www.omim.org/entry/613815"},{"mim_id":"613677","title":"HYPERALDOSTERONISM, FAMILIAL, TYPE III; HALD3","url":"https://www.omim.org/entry/613677"},{"mim_id":"610613","title":"CYTOCHROME P450, SUBFAMILY XIB, POLYPEPTIDE 1; CYP11B1","url":"https://www.omim.org/entry/610613"},{"mim_id":"610600","title":"CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY","url":"https://www.omim.org/entry/610600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"adrenal gland","ntpm":178.8}],"url":"https://www.proteinatlas.org/search/CYP11B2"},"hgnc":{"alias_symbol":["CYP11BL","CPN2","P-450C18","P450aldo","ALDOS"],"prev_symbol":["CYP11B"]},"alphafold":{"accession":"P19099","domains":[{"cath_id":"1.10.630.10","chopping":"39-502","consensus_level":"medium","plddt":93.5718,"start":39,"end":502}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19099","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19099-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19099-F1-predicted_aligned_error_v6.png","plddt_mean":89.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP11B2","jax_strain_url":"https://www.jax.org/strain/search?query=CYP11B2"},"sequence":{"accession":"P19099","fasta_url":"https://rest.uniprot.org/uniprotkb/P19099.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19099/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19099"}},"corpus_meta":[{"pmid":"1775135","id":"PMC_1775135","title":"The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex.","date":"1991","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/1775135","citation_count":316,"is_preprint":false},{"pmid":"24325867","id":"PMC_24325867","title":"Development of monoclonal antibodies against human CYP11B1 and CYP11B2.","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24325867","citation_count":248,"is_preprint":false},{"pmid":"9494027","id":"PMC_9494027","title":"Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function.","date":"1998","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/9494027","citation_count":176,"is_preprint":false},{"pmid":"7588407","id":"PMC_7588407","title":"Haplotype analysis of CYP11B2.","date":"1995","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/7588407","citation_count":168,"is_preprint":false},{"pmid":"9139807","id":"PMC_9139807","title":"Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements.","date":"1997","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9139807","citation_count":165,"is_preprint":false},{"pmid":"2256920","id":"PMC_2256920","title":"Cloning and expression of a cDNA for human cytochrome P-450aldo as related to primary aldosteronism.","date":"1990","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2256920","citation_count":150,"is_preprint":false},{"pmid":"1594605","id":"PMC_1594605","title":"Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1594605","citation_count":150,"is_preprint":false},{"pmid":"9931115","id":"PMC_9931115","title":"Genetic polymorphism of CYP11B2 gene and hypertension in Japanese.","date":"1999","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/9931115","citation_count":115,"is_preprint":false},{"pmid":"23443813","id":"PMC_23443813","title":"Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23443813","citation_count":107,"is_preprint":false},{"pmid":"27872236","id":"PMC_27872236","title":"Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).","date":"2016","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/27872236","citation_count":91,"is_preprint":false},{"pmid":"11841224","id":"PMC_11841224","title":"Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11841224","citation_count":82,"is_preprint":false},{"pmid":"10720581","id":"PMC_10720581","title":"Lys(173)Arg and -344T/C variants of CYP11B2 in Japanese patients with low-renin hypertension.","date":"2000","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/10720581","citation_count":81,"is_preprint":false},{"pmid":"16570918","id":"PMC_16570918","title":"Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.","date":"2006","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16570918","citation_count":71,"is_preprint":false},{"pmid":"8439335","id":"PMC_8439335","title":"Congenitally defective aldosterone biosynthesis in humans: inactivation of the P-450C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8439335","citation_count":70,"is_preprint":false},{"pmid":"9506770","id":"PMC_9506770","title":"Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9506770","citation_count":70,"is_preprint":false},{"pmid":"9745430","id":"PMC_9745430","title":"Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9745430","citation_count":67,"is_preprint":false},{"pmid":"11914098","id":"PMC_11914098","title":"Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.","date":"2002","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11914098","citation_count":64,"is_preprint":false},{"pmid":"10720580","id":"PMC_10720580","title":"CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism.","date":"2000","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/10720580","citation_count":60,"is_preprint":false},{"pmid":"12457455","id":"PMC_12457455","title":"Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas.","date":"2002","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12457455","citation_count":59,"is_preprint":false},{"pmid":"12817181","id":"PMC_12817181","title":"Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension.","date":"2003","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/12817181","citation_count":59,"is_preprint":false},{"pmid":"26756116","id":"PMC_26756116","title":"A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism.","date":"2016","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26756116","citation_count":58,"is_preprint":false},{"pmid":"16220979","id":"PMC_16220979","title":"Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16220979","citation_count":58,"is_preprint":false},{"pmid":"18974272","id":"PMC_18974272","title":"Differential effects of high and low steroidogenic factor-1 expression on CYP11B2 expression and aldosterone production in adrenocortical cells.","date":"2008","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18974272","citation_count":50,"is_preprint":false},{"pmid":"26471128","id":"PMC_26471128","title":"Antiaging Gene Klotho Regulates Adrenal CYP11B2 Expression and Aldosterone Synthesis.","date":"2015","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/26471128","citation_count":49,"is_preprint":false},{"pmid":"11725161","id":"PMC_11725161","title":"Aldosterone synthase gene (CYP11B2) C-334T polymorphism, ambulatory blood pressure and nocturnal decline in blood pressure in the general Japanese population: the Ohasama Study.","date":"2001","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/11725161","citation_count":49,"is_preprint":false},{"pmid":"14736447","id":"PMC_14736447","title":"Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension.","date":"2004","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/14736447","citation_count":48,"is_preprint":false},{"pmid":"1346492","id":"PMC_1346492","title":"Congenitally defective aldosterone biosynthesis in humans: the involvement of point mutations of the P-450C18 gene (CYP11B2) in CMO II deficient patients.","date":"1992","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1346492","citation_count":47,"is_preprint":false},{"pmid":"12444540","id":"PMC_12444540","title":"Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension.","date":"2002","source":"Journal of human hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/12444540","citation_count":46,"is_preprint":false},{"pmid":"7485152","id":"PMC_7485152","title":"Mutation T318M in the CYP11B2 gene encoding P450c11AS (aldosterone synthase) causes corticosterone methyl oxidase II deficiency.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7485152","citation_count":46,"is_preprint":false},{"pmid":"10608469","id":"PMC_10608469","title":"Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST).","date":"1999","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/10608469","citation_count":46,"is_preprint":false},{"pmid":"15611122","id":"PMC_15611122","title":"Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15611122","citation_count":45,"is_preprint":false},{"pmid":"12788845","id":"PMC_12788845","title":"A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12788845","citation_count":45,"is_preprint":false},{"pmid":"10720582","id":"PMC_10720582","title":"Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction.","date":"2000","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/10720582","citation_count":44,"is_preprint":false},{"pmid":"15545843","id":"PMC_15545843","title":"Multiple Polymorphisms in the renin- angiotensin-aldosterone system (ACE, CYP11B2, AGTR1) and their contribution to hypertension in African Americans and Latinos in the multiethnic cohort.","date":"2004","source":"The American journal of the medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15545843","citation_count":43,"is_preprint":false},{"pmid":"21106862","id":"PMC_21106862","title":"Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production.","date":"2011","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21106862","citation_count":42,"is_preprint":false},{"pmid":"16179417","id":"PMC_16179417","title":"The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart.","date":"2005","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16179417","citation_count":41,"is_preprint":false},{"pmid":"17296872","id":"PMC_17296872","title":"Polymorphism of CYP11B2 determines salt sensitivity in Japanese.","date":"2007","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/17296872","citation_count":41,"is_preprint":false},{"pmid":"24900631","id":"PMC_24900631","title":"Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.","date":"2013","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24900631","citation_count":39,"is_preprint":false},{"pmid":"11196473","id":"PMC_11196473","title":"Regulation of human CYP11B2 and CYP11B1: comparing the role of the common CRE/Ad1 element.","date":"2000","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/11196473","citation_count":37,"is_preprint":false},{"pmid":"20598712","id":"PMC_20598712","title":"Association of the -344C/T aldosterone synthase (CYP11B2) gene variant with hypertension and stroke.","date":"2010","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20598712","citation_count":37,"is_preprint":false},{"pmid":"29202495","id":"PMC_29202495","title":"Disordered CYP11B2 Expression in Primary Aldosteronism.","date":"2017","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/29202495","citation_count":36,"is_preprint":false},{"pmid":"25102047","id":"PMC_25102047","title":"Computational analysis of functional single nucleotide polymorphisms associated with the CYP11B2 gene.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25102047","citation_count":36,"is_preprint":false},{"pmid":"15134824","id":"PMC_15134824","title":"The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15134824","citation_count":35,"is_preprint":false},{"pmid":"15055249","id":"PMC_15055249","title":"CYP11B2 polymorphisms and home blood pressure in a population-based cohort in Japanese: the Ohasama study.","date":"2004","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15055249","citation_count":35,"is_preprint":false},{"pmid":"10577993","id":"PMC_10577993","title":"Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction.","date":"1999","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/10577993","citation_count":35,"is_preprint":false},{"pmid":"26597777","id":"PMC_26597777","title":"Intratumoral heterogeneity of steroidogenesis in aldosterone-producing adenoma revealed by intensive double- and triple-immunostaining for CYP11B2/B1 and CYP17.","date":"2015","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26597777","citation_count":34,"is_preprint":false},{"pmid":"15238568","id":"PMC_15238568","title":"Genetic variation in CYP11B2 and AT1R influences heart rate variability conditional on sodium excretion.","date":"2004","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/15238568","citation_count":34,"is_preprint":false},{"pmid":"8969900","id":"PMC_8969900","title":"Calcium regulates human CYP11B2 transcription.","date":"1996","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/8969900","citation_count":33,"is_preprint":false},{"pmid":"7588405","id":"PMC_7588405","title":"Localization of P450aldo and P45011 beta in normal and regenerating rat adrenal cortex.","date":"1995","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/7588405","citation_count":30,"is_preprint":false},{"pmid":"19622340","id":"PMC_19622340","title":"Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.","date":"2009","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19622340","citation_count":30,"is_preprint":false},{"pmid":"27754862","id":"PMC_27754862","title":"Hypomethylation of CYP11B2 in Aldosterone-Producing Adenoma.","date":"2016","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/27754862","citation_count":30,"is_preprint":false},{"pmid":"26047574","id":"PMC_26047574","title":"Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice.","date":"2015","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26047574","citation_count":30,"is_preprint":false},{"pmid":"15614025","id":"PMC_15614025","title":"Association of peripheral and central arterial wave reflections with the CYP11B2 -344C allele and sodium excretion.","date":"2004","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15614025","citation_count":30,"is_preprint":false},{"pmid":"36982850","id":"PMC_36982850","title":"Molecular and Epigenetic Control of Aldosterone Synthase, CYP11B2 and 11-Hydroxylase, CYP11B1.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36982850","citation_count":29,"is_preprint":false},{"pmid":"33925539","id":"PMC_33925539","title":"DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33925539","citation_count":29,"is_preprint":false},{"pmid":"24768260","id":"PMC_24768260","title":"Regulation of CYP11B1 and CYP11B2 steroidogenic genes by hypoxia-inducible miR-10b in H295R cells.","date":"2014","source":"Marine pollution bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/24768260","citation_count":28,"is_preprint":false},{"pmid":"15643128","id":"PMC_15643128","title":"CYP11B2 gene polymorphisms and hypertension in highlanders accustomed to high salt intake.","date":"2005","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15643128","citation_count":27,"is_preprint":false},{"pmid":"19151144","id":"PMC_19151144","title":"High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome.","date":"2009","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/19151144","citation_count":27,"is_preprint":false},{"pmid":"17980006","id":"PMC_17980006","title":"Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17980006","citation_count":26,"is_preprint":false},{"pmid":"35127376","id":"PMC_35127376","title":"Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35127376","citation_count":25,"is_preprint":false},{"pmid":"15985365","id":"PMC_15985365","title":"The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.","date":"2005","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15985365","citation_count":24,"is_preprint":false},{"pmid":"16118341","id":"PMC_16118341","title":"Association of Lys173Arg polymorphism with CYP11B2 expression in normal adrenal glands and aldosterone-producing adenomas.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16118341","citation_count":23,"is_preprint":false},{"pmid":"27793677","id":"PMC_27793677","title":"Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27793677","citation_count":22,"is_preprint":false},{"pmid":"32289837","id":"PMC_32289837","title":"Immunohistochemistry of the Human Adrenal CYP11B2 in Normal Individuals and in Patients with Primary Aldosteronism.","date":"2020","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/32289837","citation_count":22,"is_preprint":false},{"pmid":"1423351","id":"PMC_1423351","title":"Synthesis of the antibiotic cortalcerone from D-glucose using pyranose 2-oxidase and a novel fungal enzyme, aldos-2-ulose dehydratase.","date":"1992","source":"Carbohydrate research","url":"https://pubmed.ncbi.nlm.nih.gov/1423351","citation_count":21,"is_preprint":false},{"pmid":"16765146","id":"PMC_16765146","title":"Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors.","date":"2006","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16765146","citation_count":21,"is_preprint":false},{"pmid":"27853054","id":"PMC_27853054","title":"Expression of CYP11B2 in Aldosterone-Producing Adrenocortical Adenoma: Regulatory Mechanisms and Clinical Significance.","date":"2016","source":"The Tohoku journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27853054","citation_count":20,"is_preprint":false},{"pmid":"30561227","id":"PMC_30561227","title":"Association of aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population.","date":"2018","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30561227","citation_count":20,"is_preprint":false},{"pmid":"9029716","id":"PMC_9029716","title":"Expression of cytochromes P450aldo and P45011 beta in rat adrenal gland during late gestational and neonatal stages.","date":"1997","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/9029716","citation_count":19,"is_preprint":false},{"pmid":"11701710","id":"PMC_11701710","title":"Congenital hyperreninemic hypoaldosteronism unlinked to the aldosterone synthase (CYP11B2) gene.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11701710","citation_count":19,"is_preprint":false},{"pmid":"24694176","id":"PMC_24694176","title":"The clinical significance of aldosterone synthase deficiency: report of a novel mutation in the CYP11B2 gene.","date":"2014","source":"BMC endocrine disorders","url":"https://pubmed.ncbi.nlm.nih.gov/24694176","citation_count":19,"is_preprint":false},{"pmid":"19117407","id":"PMC_19117407","title":"Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease.","date":"2009","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19117407","citation_count":18,"is_preprint":false},{"pmid":"19407459","id":"PMC_19407459","title":"Association between aldosterone synthase CYP11B2 polymorphism and essential hypertension in Chinese: a meta-analysis.","date":"2009","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/19407459","citation_count":18,"is_preprint":false},{"pmid":"17003099","id":"PMC_17003099","title":"CYP11B2 -344T/C gene polymorphism and blood pressure in patients with acromegaly.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17003099","citation_count":17,"is_preprint":false},{"pmid":"33682891","id":"PMC_33682891","title":"Long-chain noncoding RNA-GAS5/hsa-miR-138-5p attenuates high glucose-induced cardiomyocyte damage by targeting CYP11B2.","date":"2021","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/33682891","citation_count":17,"is_preprint":false},{"pmid":"29665181","id":"PMC_29665181","title":"MiR-193a-3p functions as a tumour suppressor in human aldosterone-producing adrenocortical adenoma by down-regulating CYP11B2.","date":"2018","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29665181","citation_count":17,"is_preprint":false},{"pmid":"24472523","id":"PMC_24472523","title":"Aberrant gonadotropin-releasing hormone receptor (GnRHR) expression and its regulation of CYP11B2 expression and aldosterone production in adrenal aldosterone-producing adenoma (APA).","date":"2014","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24472523","citation_count":17,"is_preprint":false},{"pmid":"20224556","id":"PMC_20224556","title":"Associations of the -344 T>C and the 3097 G>A polymorphisms of CYP11B2 gene with hypertension, type 2 diabetes, and metabolic syndrome in a French population.","date":"2010","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20224556","citation_count":17,"is_preprint":false},{"pmid":"30974191","id":"PMC_30974191","title":"Expression of aldosterone synthase CYP11B2 was inversely correlated with longevity.","date":"2019","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30974191","citation_count":16,"is_preprint":false},{"pmid":"29630094","id":"PMC_29630094","title":"MiR-4421 regulates the progression of preeclampsia by regulating CYP11B2.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29630094","citation_count":16,"is_preprint":false},{"pmid":"34743356","id":"PMC_34743356","title":"Expression of CYP11B1 and CYP11B2 in adrenal adenoma correlates with clinical characteristics of primary aldosteronism.","date":"2021","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34743356","citation_count":15,"is_preprint":false},{"pmid":"9408886","id":"PMC_9408886","title":"Expression of 11 beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in the human fetal adrenal.","date":"1997","source":"Journal of the Society for Gynecologic Investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9408886","citation_count":15,"is_preprint":false},{"pmid":"31302112","id":"PMC_31302112","title":"Analysis of novel heterozygous mutations in the CYP11B2 gene causing congenital aldosterone synthase deficiency and literature review.","date":"2019","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/31302112","citation_count":15,"is_preprint":false},{"pmid":"36036158","id":"PMC_36036158","title":"Changes of the CYP11B2 Expressing Zona Glomerulosa in Human Adrenals From Birth to 40 Years of Age.","date":"2022","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/36036158","citation_count":15,"is_preprint":false},{"pmid":"11146369","id":"PMC_11146369","title":"CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis.","date":"2000","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/11146369","citation_count":14,"is_preprint":false},{"pmid":"17762647","id":"PMC_17762647","title":"Skinfold thickness and blood pressure across C-344T polymorphism of CYP11B2 gene.","date":"2007","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/17762647","citation_count":14,"is_preprint":false},{"pmid":"26066897","id":"PMC_26066897","title":"Chimeric CYP11B2/CYP11B1 causing 11β-hydroxylase deficiency in Chinese patients with congenital adrenal hyperplasia.","date":"2015","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/26066897","citation_count":14,"is_preprint":false},{"pmid":"23135028","id":"PMC_23135028","title":"Association of CYP11B2 gene polymorphism with ischemic stroke in the north Chinese Han population.","date":"2012","source":"Neurology India","url":"https://pubmed.ncbi.nlm.nih.gov/23135028","citation_count":13,"is_preprint":false},{"pmid":"31096184","id":"PMC_31096184","title":"miRNA299 involvement in CYP11B2 expression in aldosterone-producing adenoma.","date":"2019","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31096184","citation_count":12,"is_preprint":false},{"pmid":"22079243","id":"PMC_22079243","title":"Regulation of human CYP11B1 and CYP11B2 promoters by transposable elements and conserved cis elements.","date":"2011","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/22079243","citation_count":12,"is_preprint":false},{"pmid":"19116236","id":"PMC_19116236","title":"A novel CYP11B2 gene mutation in an Asian family with aldosterone synthase deficiency.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19116236","citation_count":12,"is_preprint":false},{"pmid":"20339375","id":"PMC_20339375","title":"Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism.","date":"2010","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20339375","citation_count":12,"is_preprint":false},{"pmid":"7779756","id":"PMC_7779756","title":"Stable expression of rat cytochrome P450 11 beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in MA-10 cells.","date":"1995","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7779756","citation_count":12,"is_preprint":false},{"pmid":"27125452","id":"PMC_27125452","title":"Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.","date":"2016","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27125452","citation_count":12,"is_preprint":false},{"pmid":"26686590","id":"PMC_26686590","title":"Analysis of the gene polymorphism of aldosterone synthase (CYP11B2) and atrial natriuretic peptide (ANP) in women with preeclampsia.","date":"2015","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/26686590","citation_count":12,"is_preprint":false},{"pmid":"26936515","id":"PMC_26936515","title":"Novel mutations in the CYP11B2 gene causing aldosterone synthase deficiency.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26936515","citation_count":12,"is_preprint":false},{"pmid":"9430819","id":"PMC_9430819","title":"Expression of aldosterone synthase cytochrome P450 (P450aldo) mRNA in rat adrenal glomerulosa cells by angiotensin II type 1 receptor.","date":"1997","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/9430819","citation_count":11,"is_preprint":false},{"pmid":"21228735","id":"PMC_21228735","title":"Genetic polymorphism of CYP11B2 gene and stroke in the Han Chinese population and a meta-analysis.","date":"2011","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/21228735","citation_count":11,"is_preprint":false},{"pmid":"23235923","id":"PMC_23235923","title":"Control of CYP11B2/CYP11B1 expression ratio and consequences for the zonation of the adrenal cortex.","date":"2012","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/23235923","citation_count":11,"is_preprint":false},{"pmid":"37372364","id":"PMC_37372364","title":"Association between Aldosterone Synthase (CYP11B2) Gene Polymorphism and Hypertension in Pashtun Ethnic Population of Khyber Pakhtunkwha, Pakistan.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37372364","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":57299,"output_tokens":6821,"usd":0.137106,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15737,"output_tokens":3531,"usd":0.08348,"stage2_stop_reason":"end_turn"},"total_usd":0.220586,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"CYP11B2 protein (P450aldo) catalyzes all three steps required for aldosterone biosynthesis from deoxycorticosterone: 11β-hydroxylation, 18-hydroxylation, and 18-oxidation. Expression of CYP11B2 cDNA in COS-1 cells demonstrated that only CYP11B2 (not CYP11B1) could synthesize aldosterone from deoxycorticosterone, and CYP11B2 could also 18-hydroxylate cortisol/corticosterone.\",\n      \"method\": \"Heterologous cDNA expression in COS-1 cells with steroid product analysis\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic reconstitution in cell expression system; replicated in multiple independent studies (PMID:2256920, 1594605)\",\n      \"pmids\": [\"1775135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"CYP11B2 (P-450aldo) expressed in COS-7 cells preferentially catalyzes the complete conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone, whereas CYP11B1 (P-450(11)β) substantially fails to produce aldosterone from the same substrate.\",\n      \"method\": \"Heterologous cDNA expression in COS-7 cells with steroid product analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic reconstitution in cell expression system; consistent with multiple independent replications\",\n      \"pmids\": [\"2256920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Mutations R181W and V386A in CYP11B2 cause CMO-II deficiency: R181W reduces 18-hydroxylase and abolishes 18-oxidase activities while leaving 11β-hydroxylase activity intact; V386A causes a small reduction in 18-hydroxycorticosterone production. Both mutations together compound to eliminate aldosterone synthesis.\",\n      \"method\": \"Site-directed mutagenesis of CYP11B2 cDNA with expression in cultured cells and steroid product analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — active-site mutagenesis with in vitro activity assay, confirmed in multiple affected kindreds\",\n      \"pmids\": [\"1594605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A 5-nucleotide deletion in exon 1 of CYP11B2 causes a frameshift and premature stop codon, resulting in complete absence of P-450C18 protein and total lack of aldosterone biosynthesis (CMO-I deficiency), demonstrating CYP11B2 is the sole enzyme for corticosterone methyl oxidase I activity.\",\n      \"method\": \"Molecular genetic analysis (PCR, sequencing, RFLP) of patient CYP11B2 gene\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function mutation with defined biochemical phenotype; no in vitro reconstitution of null allele but frameshift abolishing protein is definitive\",\n      \"pmids\": [\"8439335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The T318M mutation in CYP11B2 causes CMO-II deficiency. When expressed singly and in parental allele pairs in cDNA expression vectors, neither the T318M/V386A allele nor the R181W/ΔC372 allele showed measurable enzymatic activity, yet the clinical phenotype is CMO-II rather than CMO-I, suggesting other factors modulate phenotypic expression.\",\n      \"method\": \"Site-directed mutagenesis and cDNA expression with in vitro steroid activity assay\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mutagenesis; single lab, limited replication\",\n      \"pmids\": [\"7485152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Human CYP11B2 expressed in fission yeast (Schizosaccharomyces pombe) localizes to mitochondria via its endogenous signal sequence, and converts 11-deoxycorticosterone to corticosterone, 18-hydroxycorticosterone, and aldosterone in vivo. A fission yeast ferredoxin-domain protein (etp1) was identified that can functionally replace adrenodoxin as an electron donor to CYP11B2 in a reconstituted steroid hydroxylation assay.\",\n      \"method\": \"Heterologous expression in S. pombe, Western blot/fluorescence/electron microscopy for localization, in vitro reconstituted steroid hydroxylation assay with bacterially expressed etp1\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution of electron transfer to CYP11B2 with orthologous protein, confirmed by multiple localization methods and in vivo substrate conversion\",\n      \"pmids\": [\"11841224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Angiotensin II and potassium regulate CYP11B2 transcription through two cis-elements in the 5'-flanking region: a CRE-like element at -71/-64 (binding CREB proteins) and an SF-1/COUP-TF binding element at -129/-114 (Ad5). Both calcium and cAMP signaling pathways converge on these same elements to drive CYP11B2 expression.\",\n      \"method\": \"Transient transfection with luciferase reporter constructs, deletion/mutation analysis, DNase I footprinting, electrophoretic mobility shift assay (EMSA) in H295R cells\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (reporter assay, EMSA, footprinting, mutation analysis) in relevant cell line\",\n      \"pmids\": [\"9139807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Calcium signaling pathways (activated by Ang II, K+, BAYK8644, ionomycin) regulate human CYP11B2 transcription in H295R adrenocortical cells. Protein kinase C activation did not alter CYP11B2 reporter gene expression.\",\n      \"method\": \"Transient transfection of luciferase reporter construct with CYP11B2 5'-flanking DNA in H295R and Y-1 adrenocortical cell lines\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter gene assay with pharmacological pathway dissection; single lab, multiple conditions tested\",\n      \"pmids\": [\"8969900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"COUP-TFI binds the Ad5 element (-129/-114) of the CYP11B2 promoter and activates transcription. Ubc9 (SUMO E2 conjugase) and PIAS1 (SUMO E3 ligase) interact with COUP-TFI and act as transcriptional coactivators of CYP11B2; sumoylation activity is separable from coactivator function. All three proteins are recruited to the endogenous CYP11B2 promoter in ChIP assays.\",\n      \"method\": \"EMSA, transient transfection, yeast two-hybrid, coimmunoprecipitation, chromatin immunoprecipitation (ChIP), siRNA knockdown in H295R cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including ChIP, Co-IP, EMSA, reporter assay, and siRNA loss-of-function\",\n      \"pmids\": [\"15611122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SF-1 (steroidogenic factor-1) overexpression dramatically inhibits CYP11B2 mRNA expression and aldosterone production in adrenocortical H295R cells, while SF-1 knockdown by siRNA reverses this inhibition. Conversely, SF-1 overexpression increases CYP11B1 expression, demonstrating opposing regulatory roles. A minimal level of SF-1 is required for basal expression of both genes.\",\n      \"method\": \"Doxycycline-inducible SF-1 overexpression, siRNA knockdown, real-time RT-PCR, immunoassay in H295R/TR/SF-1 cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain- and loss-of-function with quantitative mRNA and hormone readouts; multiple orthogonal approaches\",\n      \"pmids\": [\"18974272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PPARγ suppresses CYP11B2 expression and aldosterone secretion via the Ad1/CRE element in the CYP11B2 5'-flanking region. PPARγ activation by pioglitazone inhibits CaMKI-mediated CYP11B2 transcriptional activation. The PPARγ L466A/E469A mutant abolishes this suppression, indicating ligand-binding domain requirement.\",\n      \"method\": \"Transient transfection with promoter-reporter constructs, PPARγ overexpression/mutation, CaMKI transfection, pharmacological inhibition in H295R cells\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with mutagenesis and overexpression; single lab, multiple pathway conditions\",\n      \"pmids\": [\"21106862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Klotho (KL) regulates CYP11B2 expression in adrenal zona glomerulosa cells: KL silencing upregulates and KL overexpression downregulates CYP11B2 in human adrenocortical cells. KL deficiency decreases SF-1 expression (a negative regulator of CYP11B2) and increases ATF2 phosphorylation (a positive regulator), providing a mechanistic link. KL and CYP11B2 proteins co-localize in adrenal zona glomerulosa cells.\",\n      \"method\": \"siRNA knockdown, overexpression, Western blot, immunofluorescence co-localization, immunoassay in human adrenocortical cells and KL+/- mice\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with mechanistic follow-up; single lab, in vitro and in vivo\",\n      \"pmids\": [\"26471128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The CRE/Ad1 cis-element in the CYP11B2 promoter is required for basal expression but is not sufficient for hormonal regulation by angiotensin II; mutation of this element abolishes basal expression while retaining agonist response, suggesting additional cis-elements mediate Ang II induction. Both ATF-2 and CREB bind this element, but only ATF-2 complexes match those in H295R nuclear extract.\",\n      \"method\": \"Transient transfection with reporter constructs, promoter deletion/mutation, EMSA with recombinant transcription factors and H295R nuclear extracts\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with mutagenesis and EMSA; single lab, multiple methods\",\n      \"pmids\": [\"11196473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CYP11B2 requires the adrenodoxin/adrenodoxin reductase electron transfer system for catalytic activity. A stable cell line co-expressing CYP11B2 with adrenodoxin and adrenodoxin reductase was established, demonstrating that FAD286 inhibits CYP11B2 competitively with a Ki of 0.8 nM using 11-deoxycorticosterone as substrate.\",\n      \"method\": \"Stable cell transfection, in vitro enzyme activity assay with radiolabeled substrate, competitive kinetics analysis\",\n      \"journal\": \"Analytical biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted assay with kinetic characterization; single lab\",\n      \"pmids\": [\"19622340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CYP11B2 (P450aldo) is localized specifically to zona glomerulosa cells of the rat adrenal cortex, while CYP11B1 (P45011β) is in zona fasciculata. A novel cell layer lacking both enzymes exists between zones and contains adrenal stem cells. Angiotensin II stimulation (via Na-deficiency) increases P450aldo-containing zona glomerulosa cell number and triggers proliferation of cells in this intermediate zone, which then migrate outward.\",\n      \"method\": \"Immunohistochemistry, double immunostaining, BrdU pulse-chase in rat adrenal sections\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with functional consequence (proliferation response to Ang II); single lab\",\n      \"pmids\": [\"7588405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CYP11B2 (P450aldo) mRNA and protein expression in rat adrenal zona glomerulosa is upregulated approximately 8.5-fold by dietary sodium restriction (which elevates angiotensin II) and this upregulation is blocked by the selective AT1 receptor antagonist E4177 but not by the AT2 antagonist PD123177, demonstrating that CYP11B2 expression is regulated specifically through the AT1 receptor.\",\n      \"method\": \"RT-PCR with specific primers, immunoblot analysis, pharmacological receptor antagonism in rat adrenal gland\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological dissection with quantitative mRNA and protein readouts; single lab\",\n      \"pmids\": [\"9430819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GnRH acting through ectopically expressed GnRH receptor (GnRHR) increases CYP11B2 reporter activity and aldosterone production in H295R cells in a concentration-dependent manner. These effects are blocked by calcium signaling inhibitors KN93 and calmidazolium, placing GnRHR-mediated CYP11B2 regulation upstream of the calcium/calmodulin kinase pathway.\",\n      \"method\": \"Transient transfection with CYP11B2 reporter, doxycycline-inducible GnRHR cell line, pharmacological inhibition, RT-PCR, immunoassay\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with pharmacological pathway placement; single lab, multiple conditions\",\n      \"pmids\": [\"24472523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Atractylenolide-I (AT-I) selectively covalently binds CYP11B2 at Cys450 (via C8/C9 epoxide intermediate) in the catalytic pocket, disrupts heme-CYP11B2 interaction, and inactivates aldosterone synthesis. The selectivity over CYP11B1 is due to Ala320 in CYP11B2 (versus a different residue in CYP11B1). This covalent inhibition suppresses aldosterone but not cortisol production.\",\n      \"method\": \"Chemical biology covalent binding studies, molecular docking, cell-based steroid synthesis assay, in vivo hyperaldosteronism model\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mechanistic covalent binding characterization with structural rationale and functional readout; single lab\",\n      \"pmids\": [\"35127376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Stable expression of CYP11B2 cDNA in MA-10 Leydig tumor cells demonstrates the enzyme converts DOC to corticosterone, 18-OH-corticosterone, aldosterone, and small amounts of 18-OH-DOC. Corticosterone is more efficiently converted to 18-OH-corticosterone than is DOC. CYP11B2 (but not CYP11B1) can also transform 18-OH-DOC to 18-OH-corticosterone but cannot convert 18-OH-DOC to aldosterone.\",\n      \"method\": \"Stable transfection of MA-10 cells with CYP11B2 cDNA, enzyme activity assay with radiolabeled substrates, Northern blot\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — stable reconstitution system with substrate panel; single lab\",\n      \"pmids\": [\"7779756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CYP11B2 metabolizes spironolactone (producing 11β-OH-, 18-OH-, and 19-OH-spironolactone) and canrenone (producing 11β-OH-, 18-OH-canrenone, and the CYP11B2-specific 11β,18-diOH-canrenone) via its hydroxylase activities. Binding constants for these exogenous substrates are comparable to natural substrates. 11β-OH-spironolactone retains mineralocorticoid receptor antagonist activity, while other hydroxylation products lose antagonist properties.\",\n      \"method\": \"In vitro assay with purified CYP11B2, spectroscopic binding assay, preparative-scale whole-cell biotransformation, HPLC purification, NMR structural characterization of metabolites, mineralocorticoid receptor transactivation assay\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — purified enzyme assay with structural characterization of products by NMR; multiple substrates and functional validation\",\n      \"pmids\": [\"27125452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The S308P mutation in CYP11B2 (located within alpha-helix I near the heme-binding active site per structural modeling) causes complete loss of enzyme activity when expressed in vitro. However, dexamethasone suppressed residual aldosterone/metabolite levels in affected subjects in vivo, suggesting some mineralocorticoid biosynthesis occurs through an alternative pathway in vivo.\",\n      \"method\": \"Sequencing, in vitro functional characterization of mutant CYP11B2, structural homology modeling, in vivo dexamethasone suppression test\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of null mutant; single lab, limited replication\",\n      \"pmids\": [\"19116236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The CYP11B2 and CYP11B1 promoters diverged due to insertion of Alu and L1 transposable elements. Alu elements act as enhancers for both genes regardless of orientation. The Ad5 and SF-1 binding elements in the proximal core promoter are required for basal expression; mutation of Ad5 reduces activity to minimal levels. ERRα is identified as the transcription factor binding the Ad5 site during basal CYP11B2 expression.\",\n      \"method\": \"Promoter deletion/mutation reporter assays, sequence analysis, transcription factor identification by reporter assay in H295R cells\",\n      \"journal\": \"Steroids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter dissection with mutagenesis; single lab, multiple elements tested\",\n      \"pmids\": [\"22079243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-193a-3p directly targets the 3'-UTR of CYP11B2 mRNA (validated by luciferase reporter with wild-type vs. mutated binding site) and downregulates CYP11B2 mRNA and protein expression. Overexpression of miR-193a-3p in H295R cells inhibits aldosterone secretion, cell proliferation, induces G1-phase arrest, and promotes apoptosis; these effects are reversed by CYP11B2 overexpression.\",\n      \"method\": \"Luciferase 3'-UTR reporter assay, qRT-PCR, Western blot, miR mimic transfection, flow cytometry, ELISA in H295R cells\",\n      \"journal\": \"International journal of experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'-UTR luciferase validation with rescue experiment; single lab, multiple functional readouts\",\n      \"pmids\": [\"29665181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-10b (hypoxia-inducible) negatively regulates CYP11B2 (and CYP11B1) mRNA by targeting their 3'-UTRs, as validated by luciferase reporter assays with CYP11B2 3'-UTR constructs combined with miR-10b overexpression and knockdown in H295R cells.\",\n      \"method\": \"miRNA array profiling, luciferase 3'-UTR reporter assay, miR overexpression/knockdown in H295R cells\",\n      \"journal\": \"Marine pollution bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'-UTR reporter validation with gain- and loss-of-function; single lab\",\n      \"pmids\": [\"24768260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The CYP11B2 promoter contains a polymorphism at position -344 that influences binding of the transcriptional regulatory protein SF-1. This polymorphism and an intron 2 gene conversion (replacing CYP11B2 sequence with CYP11B1 sequence) are in linkage disequilibrium, defining haplotypes with population frequency differences between Blacks and Whites.\",\n      \"method\": \"PCR-based genotyping, linkage disequilibrium analysis, transcription factor binding inference from sequence analysis\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — SF-1 binding at -344 inferred from sequence; no direct binding experiment reported in this abstract\",\n      \"pmids\": [\"7588407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RO6836191 is a competitive inhibitor of CYP11B2 (aldosterone synthase) with Ki of 13 nM and >100-fold selectivity over CYP11B1 in vitro. In cynomolgus monkeys, it inhibits aldosterone synthesis without affecting ACTH-stimulated cortisol. In healthy human subjects, it completely suppresses plasma and urine aldosterone across a dose range without affecting cortisol up to 360 mg.\",\n      \"method\": \"In vitro enzyme inhibition assay (Ki determination), in vivo pharmacology in cynomolgus monkeys, Phase I clinical study in healthy volunteers\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — competitive kinetics in vitro confirmed by in vivo pharmacology across species including humans; multiple orthogonal methods\",\n      \"pmids\": [\"27872236\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP11B2 (aldosterone synthase) is a mitochondrial cytochrome P450 enzyme localized to adrenal zona glomerulosa cells that catalyzes the three-step conversion of 11-deoxycorticosterone to aldosterone (11β-hydroxylation → 18-hydroxylation → 18-oxidation), requires adrenodoxin/adrenodoxin reductase for electron transfer, and is transcriptionally regulated by angiotensin II (via AT1R-calcium/CaMK pathway) and potassium through shared CRE/Ad1 and SF-1/COUP-TF cis-elements in its promoter, with additional regulation by SF-1 (inhibitory at high levels), PPARγ, Klotho, Ubc9/PIAS1 coactivators of COUP-TFI, and post-transcriptional control by miR-193a-3p and miR-10b targeting its 3'-UTR.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CYP11B2 (aldosterone synthase) is the mitochondrial cytochrome P450 enzyme that catalyzes the terminal steps of aldosterone biosynthesis in adrenal zona glomerulosa cells, converting 11-deoxycorticosterone to aldosterone through sequential 11β-hydroxylation, 18-hydroxylation, and 18-oxidation reactions [#0, #1]. Heterologous reconstitution established that only CYP11B2 — not the closely related CYP11B1 — completes the full conversion to aldosterone, while it can also 18-hydroxylate other steroid substrates [#0, #18]. Catalysis depends on the adrenodoxin/adrenodoxin reductase electron-transfer system [#13], and the enzyme localizes to mitochondria via its endogenous targeting sequence, where a ferredoxin-domain donor can functionally substitute for adrenodoxin [#5]. Loss-of-function mutations partition the biosynthetic defect by step: a frameshift abolishing the protein causes CMO-I deficiency (loss of corticosterone methyl oxidase I activity) [#3], whereas active-site missense mutations such as R181W, T318M, and S308P selectively impair 18-hydroxylase/18-oxidase steps to produce CMO-II deficiency [#2, #4, #20]. CYP11B2 transcription is driven by angiotensin II (acting through the AT1 receptor) and potassium via a calcium/CaMK signaling pathway that converges on a proximal CRE/Ad1 element and an SF-1/COUP-TF (Ad5) element in the 5'-flanking region [#6, #7, #15, #12]. This promoter is modulated by COUP-TFI together with Ubc9/PIAS1 coactivators [#8], by ERRα at the Ad5 site [#21], and is suppressed by high SF-1, PPARγ, and Klotho [#9, #10, #11], with post-transcriptional repression by miR-193a-3p and miR-10b targeting the 3'-UTR [#22, #23]. Its enzymatic specificity underlies the development of selective aldosterone synthase inhibitors as antihypertensive agents [#25, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established the core catalytic identity of CYP11B2 — that a single enzyme performs all three oxidative steps of aldosterone synthesis, distinguishing it from CYP11B1 which cannot.\",\n      \"evidence\": \"Heterologous cDNA expression in COS-1/COS-7 cells with steroid product analysis comparing CYP11B2 and CYP11B1\",\n      \"pmids\": [\"1775135\", \"2256920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis for the bifunctional 18-oxidase activity\", \"Did not address electron-donor requirements in vivo\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Mapped the substrate panel and intermediate flux of the enzyme, showing corticosterone is converted more efficiently than DOC and that 18-OH-DOC is not a productive intermediate for aldosterone.\",\n      \"evidence\": \"Stable transfection in MA-10 Leydig cells with radiolabeled substrate panel and Northern blot\",\n      \"pmids\": [\"7779756\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; in vitro reconstitution may not reflect zona glomerulosa kinetics\", \"No structural model for substrate channeling\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Localized CYP11B2 specifically to the zona glomerulosa and linked angiotensin II to expansion of aldosterone-producing cells, connecting enzyme expression to adrenal zonation and cell proliferation.\",\n      \"evidence\": \"Immunohistochemistry, double immunostaining, and BrdU pulse-chase in rat adrenal sections\",\n      \"pmids\": [\"7588405\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Rat model; human zonation dynamics not directly tested\", \"Stem cell migration mechanism not molecularly defined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Defined the genotype-phenotype basis for inherited aldosterone deficiency, showing protein-null mutations cause CMO-I deficiency and step-selective active-site mutations cause CMO-II deficiency.\",\n      \"evidence\": \"Patient gene analysis (frameshift) plus site-directed mutagenesis of R181W/V386A/T318M/S308P with in vitro activity assays\",\n      \"pmids\": [\"8439335\", \"1594605\", \"7485152\", \"19116236\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CMO-II vs CMO-I phenotypic distinction not fully explained by in vitro activity\", \"S308P case suggested an alternative in vivo mineralocorticoid pathway not yet identified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified the cis-regulatory architecture by which angiotensin II and potassium control CYP11B2 transcription, defining the CRE/Ad1 and SF-1/COUP-TF (Ad5) elements where calcium and cAMP pathways converge.\",\n      \"evidence\": \"Reporter assays, deletion/mutation analysis, DNase I footprinting, and EMSA in H295R cells; AT1-receptor-specific pharmacology in rat adrenal\",\n      \"pmids\": [\"9139807\", \"8969900\", \"9430819\", \"11196473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CRE/Ad1 alone insufficient for Ang II induction — additional inducible elements not fully mapped\", \"Relative contribution of ATF-2 vs CREB at the element unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Confirmed mitochondrial targeting and the electron-transfer requirement, showing a ferredoxin-domain protein can functionally replace adrenodoxin to support catalysis.\",\n      \"evidence\": \"S. pombe heterologous expression with imaging-based localization and reconstituted hydroxylation assay using bacterially expressed etp1\",\n      \"pmids\": [\"11841224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous human adrenodoxin coupling is rate-limiting in vivo not addressed\", \"No structural detail of the CYP11B2-redox partner interface\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Expanded the transcription-factor network, identifying COUP-TFI/Ubc9/PIAS1 as activators at Ad5 and SF-1 and PPARγ/Klotho as suppressors, revealing reciprocal regulation of CYP11B2 versus CYP11B1.\",\n      \"evidence\": \"EMSA, Y2H, Co-IP, ChIP, siRNA, inducible overexpression and reporter assays in H295R cells; Klotho studies in human cells and KL+/- mice\",\n      \"pmids\": [\"15611122\", \"18974272\", \"21106862\", \"26471128\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Integration of multiple opposing regulators into a single quantitative model not established\", \"Most evidence from H295R cell line; in vivo relevance of each factor varies\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established post-transcriptional control of CYP11B2 by miRNAs targeting its 3'-UTR, linking miR-193a-3p and miR-10b to aldosterone output and adrenocortical cell behavior.\",\n      \"evidence\": \"3'-UTR luciferase reporter validation, miR mimic/knockdown, rescue experiments, and functional assays in H295R cells\",\n      \"pmids\": [\"29665181\", \"24768260\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contexts driving these miRNAs in vivo not established\", \"Single-lab reporter validations\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated CYP11B2 as a tractable pharmacological target by characterizing selective competitive inhibitors and a covalent inactivator that spare CYP11B1/cortisol.\",\n      \"evidence\": \"In vitro Ki determination, structural/docking rationale (Ala320, Cys450), and in vivo pharmacology in monkeys and humans; CYP11B2 also metabolizes spironolactone/canrenone\",\n      \"pmids\": [\"27872236\", \"35127376\", \"27125452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term in vivo selectivity and resistance not addressed\", \"Structural basis of B2/B1 selectivity inferred rather than crystallographically resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The full integration of upstream GnCa signaling, the complete cis/trans regulatory network, and a high-resolution structural model of substrate/inhibitor selectivity into a unified mechanistic picture remains open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental atomic structure of human CYP11B2 in the timeline\", \"Alternative in vivo mineralocorticoid pathway implied by S308P case unidentified\", \"Quantitative hierarchy among the many activators/repressors not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 5, 13, 18, 19]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 18, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FDX1\", \"COUP-TFI\", \"Ubc9\", \"PIAS1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}